The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions

@article{Haddad2006ThePI,
  title={The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions},
  author={Abdo S. Haddad and Mellar P. Davis and Ruth L. Lagman},
  journal={Supportive Care in Cancer},
  year={2006},
  volume={15},
  pages={251-257}
}
BackgroundAdverse drug interactions are major causes of morbidity, hospitalizations, and mortality. The greatest risk of drug interactions occurs through in the cytochrome system. CYP3A4, the most prevalent cytochrome, accounts for 30–50% of drugs metabolized through type I enzymes.Materials and methodsPalliative patients received medications for symptoms and co-morbidities, many of which are substrate, inhibitors, or promoters of CYP3A4 activity and expression. A literature review on CYP3A4… 
Drug combinations with the potential to interact among cancer patients
TLDR
A comprehensive review of the literature on pharmacokinetic drug interactions between medications to palliate symptoms commonly prescribed to cancer patients that involve the CYP3A4 cytochrome enzyme suggested that drug combinations with the potential to interact are common among cancer patients.
Drug Interaction in Psycho-Oncology: Antidepressants and Antineoplastics
TLDR
Among the ADs, escitalopram, citaloprams, venlafaxine, mirtazapine and milnacipran stand out for their weak CYP 450 inhibitory potential and their safety profile in those patients.
Mechanisms and the clinical relevance of complex drug–drug interactions
TLDR
This review provides a synopsis of the pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms that underlie DDIs and describes the additive, synergistic and antagonistic mechanisms of PD-mediated DDIs.
Clinically significant drug interactions at end of life
TLDR
Understanding and anticipating potential drug interactions in end-of-life and palliative care is paramount for the health professional.
Drug Interactions in Dying Patients
TLDR
In the context of end-of-life care, the clinical relevance of DDIs differs from other clinical settings and concerns the awareness of futile and high-risk medications, as well as rational alternatives.
Drug-Drug Interactions in Prostate Cancer Treatment.
Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany.
TLDR
In the context of end-of-life care, the clinical relevance of DDIs differs from other clinical settings and most DDIs can be prevented if the prescribing physician considers a few therapeutic principles.
Opioid metabolism and clinical aspects.
  • S. Mercadante
  • Medicine, Biology
    European journal of pharmacology
  • 2015
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies
TLDR
Hepatic microsomes showed time-dependent loss of R406 and formation of para-O-demethylated R406, and the oxidative metabolism of R 406 is predominantly catalyzed by CYP3A4.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
St John's wort (Hypericum perforatum): drug interactions and clinical outcomes.
TLDR
Possible pharmacodynamic interactions with selective serotonin re-uptake inhibitors and serotonin (5-HT(1d)) receptor-agonists such as triptans used to treat migraine were identified and are associated with an increased risk of adverse reactions.
Drug interactions in dentistry: the importance of knowing your CYPs.
  • E. Hersh, P. Moore
  • Medicine, Biology
    Journal of the American Dental Association
  • 2004
TLDR
A number of clinically significant drug interactions can arise with dental therapeutic agents that act as substrates or inhibitors of the CYP450 system and the likelihood of adverse drug interactions in dentistry will increase.
Drug interactions: Proteins, pumps, and P-450s.
TLDR
The life of a drug is reviewed with emphasis on absorption, distribution, metabolism, and excretion and knowledge of which agents are likely to cause alterations in drug metabolism should help predict important potential drug interactions.
Drug interactions of the newer oral antifungal agents
  • Katz
  • Medicine, Biology
    The British journal of dermatology
  • 1999
TLDR
Terbinafine may be the most rational choice of oral antifungal agent in patients receiving concomitant medications that may adversely affect or be affected by either fluconazole or itraconazole.
Metabolism of Drugs by Cytochrome P450 3A Isoforms
TLDR
In vitro inhibition constant (Ki) values alone do not predict the magnitude of an in vivo interaction, nor whether an interaction will be of clinical importance, but SSRIs are predicted to impair clearance of the antihistamine terfenadine in humans.
Pharmacokinetic interactions of antidepressants.
  • E. Richelson
  • Biology, Psychology
    The Journal of clinical psychiatry
  • 1998
TLDR
Seven of the newest antidepressants are the serotonin selective reuptake inhibitors (fluoxetine, sertraline, paroxetines, and fluvoxamine), a postsynaptic serotonin antagonist/presynaptic serotonin reuptakes inhibitor (nefazodone), and presynaptic/postsynaptic noradrenergic/serotonergic receptor antagonist (mirtazapine).
Drug interactions and hepatitis produced by some macrolide antibiotics.
TLDR
Drug interactions involving macrolides have been mainly reported in subjects receiving troleandomycin and in a few receiving erythromycin derivatives and the following mechanism might be proposed as a hypothetical attempt to link up these various observations.
Metabolic drug interactions with new psychotropic agents
TLDR
The potential for metabolically based drug interactions of any new psychotropic agent may be anticipated on the basis of knowledge about the CYP enzymes responsible for its metabolism and about its effect on the activity of these enzymes.
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
TLDR
It appears that the chemical properties of a drug critical to CYP3A4 inactivation include formation of reactive metabolites by CYP isoenzymes, preponderance of CYP inducers and P-glycoprotein (P-gp) substrate, and occurrence of clinically significant pharmacokinetic interactions with coadministered drugs.
Macrolide Antibacterials
TLDR
Macrolide antibiotics can interact adversely with commonly used drugs, usually by altering metabolism due to complex formation and inhibition of cytochrome P-450 IIIA4 in the liver and enterocytes, and through enhanced gastric emptying due to a motilin-like effect.
...
1
2
3
4
5
...